Insights from Flagship Biosciences’ team of multidisciplinary experts.
AACR Annual Meeting 2018 Recap
Share this Post: AACR’s Annual Meeting brings us the latest and best in cancer science and medicine from institutions all over the world. This year’s
The Well-Designed Study: How Validated Biomarker Measurements are Supporting Clinical Endpoints
Share this Post: It is no secret that drug developers are under increasing pressure to discover new targeted therapies to meet high unmet medical needs,
The “One Number” Promise: Insights from the Next Generation Dx Summit Highlight the Need for Integrated, Unified and Actionable Data
Share this Post: Twenty years ago, the foundation for Next-Gen Sequencing was set. Ten years ago, advances made NGS a viable platform. Today, clinicians are
Tumor Agnostic Approval Signals New Phase for Precision Medicine
Share this Post: In an important first, the FDA recently granted accelerated approval to Keytruda® for an indication that is based on a common biomarker
WSI System clearance for primary diagnosis expands clinical application of digital pathology
Back to Blog Share this Post: On April 12, 2017, FDA granted marketing clearance for the Philips IntelliSite Pathology Solution (PIPS), the first Whole Slide
Combining Genomic Profiling and Tissue-Based Biomarker Assays to Aid in the Early Detection and Prevention of Cancer
Back to Blog Share this Post: Genomic sequencing of precancerous lesions to improve prevention and early detection of cancer was a major focus at the
